Jul 26th, 2011
In this issue:
› VivaGel® demonstrates efficacy in the treatment of bacterial vaginosis; Independent study finds link between bacterial vaginosis and HIV
› Japanese VivaGel® condom deal secures second largest condom market in the world
› Starpharma’s Priostar dendrimers improve bestselling herbicide
› Drug delivery program delivers early-stage results in improving blockbuster chemo drug.
Jul 19th, 2011
Starpharma today commented on results of a study which showed that men were three times more likely to contract HIV from their female partners if the women also had bacterial vaginosis (BV) in the three months before the men became infected.Read More
Jul 12th, 2011
Starpharma today announced encouraging results from studies applying its Priostar® dendrimer technology to the improvement of globally significant agrochemicals.
- Starpharma’s Priostar® dendrimer found to improve the effectiveness of agrochemicals including glyphosate, the most commonly used herbicide globally;
- Starpharma’s internal development program is focused on the improvement of several existing agrochemicals;
- New patent filing to extend coverage to 2029.
Jul 11th, 2011
The Age Journalist David Potts notes the resilience of biotech companies in volatile market conditions: ‘They might not make any money but, hey, that has never stopped a boom. Many biotech stocks have been surging in this sluggish sharemarket.’
Jul 7th, 2011
Herald Sun Journalist John Beveridge looks at the diverse, long term investment potential within Starpharma’s research portfolio: ‘Everybody loves to grab a bargain, but when you are aiming to make money, buying a share that is rising is a much better idea than having a constant anxiety attack about paying more than the last buyer.’
Jun 29th, 2011
Australian Life Scientist Journalist Tim Dean investigates Starpharma’s pre-clinical studies on popular chemotherapy drug, docataxel: ‘Chemotherapy drugs are big business, and Melbourne-based Starpharma is looking to get involved by applying its dendrimer technology to reformulate and improve leading therapies.’
Jun 29th, 2011
Starpharma today announced the nomination of leading anti-cancer drug docetaxel as a lead candidate in its cancer drug delivery program following encouraging early results.
- Starpharma’s dendrimers demonstrate improvements in multibillion dollar chemotherapy drug, docetaxel;
- Water solubility improved more than 2000-fold, potentially reducing serious side effects;
- Starpharma to advance a dendrimer-docetaxel formulation as a lead candidate in its drug delivery cancer program.
May 24th, 2011
Starpharma invites you to listen to an audio broadcast with Chief Executive Officer Dr Jackie Fairley, regarding the successful results of the major phase 2 clinical study that demonstrated efficacy of VivaGel® for the treatment of bacterial vaginosis (BV).
To listen to the Boardroom Radio audio broadcast please click here.Read More
May 23rd, 2011
Starpharma today announced successful results of a major phase 2 clinical study that demonstrated efficacy of VivaGel® for the treatment of bacterial vaginosis (BV).
- VivaGel® meets primary endpoint, demonstrating significant efficacy for treatment of BV
- VivaGel® expected to avoid many shortcomings of existing therapies
May 10th, 2011
Starpharma today announced that it has signed a licence agreement with Okamoto Industries Inc in relation to the VivaGel®-coated condom for the Japanese market. Okamoto is the market leader for condoms sold in Japan, the world’s second largest condom market.Read More
Apr 27th, 2011
The cash balance at 31 March 2011 was $20.1m compared to $19.7m at 31 December 2010.
The Operating & Investing cash outflow of $1.6m for the quarter includes the costs of the fully enrolled phase 2 study assessing VivaGel® as a treatment for bacterial vaginosis. Financing cash inflows of $2.0m included proceeds from the exercise of share options during the quarter.
Mar 29th, 2011
In this issue:
› Enrolment completed for Phase2 study of VivaGel® for treatment of BV
› Strengthening shareholderbase – new domestic and European investors
› Broad appeal of SPL’sdendrimer technology platform – agrochemicals and drug delivery
› Starpharma’s performance vs the market
Download: Shareholder Update: March 2011 ( pdf file, 530kb)
Mar 23rd, 2011
Starpharma today announced it had completed enrolment and all patient follow-up visits in its phase 2 study of VivaGel® for the treatment of bacterial vaginosis (BV).
This study investigated the effectiveness of VivaGel® administered once daily for seven days in the treatment of BV and enrolled 132 participants in the US. Data is now being processed and results will be available in the second quarter of this year.Read More
Mar 10th, 2011
Starpharma is today presenting at the ASX Emerging Growth conference in London.
More than 150 institutional fund managers are confirmed for the event. Starpharma is one of 18 companies participating in this invitation only event, and one of only two healthcare companies. Mesoblast is the other.
Presentation: SPL presents at ASX Emerging Growth Conference ( pdf file, 2MB)
Mar 3rd, 2011
Starpharma has been awarded $250,000 funding to enhance agrochemicals using its Priostar® dendrimers. The funding as part of the Victorian Government’s Small Technologies Industry Uptake Program (STIUP), will allow Starpharma to expand its Melbourne-based agricultural programs, further enhancing the commercial prospects of promising candidates.Read More
Feb 21st, 2011
Starpharma released its interim report and financial results for the half-year ended 31 December 2010.
- Cash position at 31 December 2010 $19.7M
- Net cash burn for the half-year $3.1M
- Operating cash outflows for the half-year $3.75M
- Reported loss $4.2M.
Jan 31st, 2011
The cash balance at 31 December 2010 was $19.7m compared to $22.8m at 30 June 2010. The Operating & Investing cash outflow of $1.5m for the quarter includes costs of the phase 2 bacterial vaginosis (BV) program. Progress with the Phase 2 BV acute-treatment study for VivaGel®, which commenced in July 2010 has been pleasing, with 90% of patients (119 from a total of 132) now enrolled.Read More
Jan 14th, 2011
Abstract: Starpharma is carving up and carving out in as many ways as possible product and application opportunities from its dendrimer chemistry platform. Dendrimers are synthetic, branch like chemical structures that can be engineered very precisely. The addition of smaller functional groups on the periphery or even with the greater structure is what makes the chemistry so versatile.
Download: Bioshares Issue 392 ( pdf file, 45kb)Read More
Dec 11th, 2010
In accordance with Listing Rule 3.13.2 and section 251AA of the Corporations Act, we advise that details of the resolutions and the proxies received in respect of each resolution considered by the Starpharma Holdings Limited Annual General Meeting are set out in the attached proxy summary.
Nov 4th, 2010
Reckitt Benckiser has announced that it has completed its £2.5bn acquisition of SSL after gaining approval from more than 85% of SSL's shareholders by last Friday. As a result, SSL is now formally part of Reckitt Benckiser and its leading global condom brand Durex will be added to Reckitt’s portfolio of health and personal care “Powerbrands” which include Nurofen, Strepsils and Clearasil.Read More
Oct 20th, 2010
Starpharma Holdings Limited (ASX:SPL, OTCQX:SPHRY) is one of 20 Australian companies, and one of only two Biotechs, selected to present at the third annual ASX Small to Mid Caps conference in Hong Kong. The ASX Hong Kong conference is part of a series of international investor events designed to showcase emerging Australian small and mid-cap listed companies to investors in Asia, Europe and the US.Read More
Sep 30th, 2010
Starpharma today announced the signing of a collaborative research agreement with leading US pharmaceutical corporation Eli Lilly and Company.
The new agreement relates to a co-development program for one of Starpharma’s dendrimer-drug conjugates.Read More
Aug 25th, 2010
Starpharma today released its annual report and financial results for the year ended 30 June 2010.
Cash reserves of $22.8 million are a result of prudent management of cash, successful capital raising and continuing partnering revenues, and interest received throughout the year.Read More
Jul 27th, 2010
Abstract: While much has been communicated about Starpharma's Vivagel product and its application as a microbicidal condom coating, the company was asked to present on the rapidly strengthening interest in the use of the company's dendrimers for the application of drug delivery.
Download: Bioshares Issue 369 ( pdf file, 26kb)